Last reviewed · How we verify
PF-07220060 + PF-07104091 combination dose escalation (pf-07220060-pf-07104091-combination-dose-escalation)
At a glance
| Generic name | pf-07220060-pf-07104091-combination-dose-escalation |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Merkel cell carcinoma
- Cervical cancer
- Biomarker-eligible patients with unresectable or metastatic melanoma
- Biomarker-eligible patients with unresectable or metastatic renal cell carcinoma
- Biomarker-eligible patients with unresectable or metastatic triple-negative breast cancer
- Biomarker-eligible patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma
- Biomarker-eligible patients with unresectable or metastatic colorectal cancer
- Biomarker-eligible patients with unresectable or metastatic hepatocellular carcinoma
- Biomarker-eligible patients with unresectable or metastatic biliary tract cancer
- Biomarker-eligible patients with unresectable or metastatic cholangiocarcinoma
- Biomarker-eligible patients with unresectable or metastatic synovial sarcoma
- Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma
- Biomarker-eligible patients with unresectable or metastatic follicular lymphoma
- Biomarker-eligible patients with unresectable or metastatic marginal zone lymphoma
- Biomarker-eligible patients with unresectable or metastatic diffuse large B-cell lymphoma
- Biomarker-eligible patients with unresectable or metastatic multiple myeloma
Common side effects
Drug interactions
- PF-07220060
- PF-07104091
- PF-07220060
- PF-07104091
- PF-07220060
- PF-07104091
- PF-07220060
- PF-07104091
- PF-07220060
- PF-07104091
- PF-07220060
- PF-07104091
Key clinical trials
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: